Thrombosis Research
Volume 121, Issue 6 , Pages 743-750 , 2008

Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?

Received 11 June 2007 ,Revised 14 July 2007 ,Accepted 18 July 2007.

References 

  1. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611–1617
  2. Galli M, Luciani G, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systemic review of the literature. Blood. 2003;101:1827–1832
  3. Lalouschek W, Schillinger M, Hsieh K, Endler G, Tentschert S, Lang W, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005;36:1405–1409
  4. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817–2821
  5. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinar M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562–3565
  6. Grossmann R, Geisen U, Merati G, Mullges W, Schambeck CM, Walter U, et al. Genetic risk factors in young adults with cryptogenic ischemic cerebrovascular disease. Blood Coagul Fibrinolysis. 2002;13:583–590
  7. Margaglione M, D'Andrea G, Giuliani , Brancaccio V, De Lucia D, Grandone E, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol. 1999;19:1751–1756
  8. Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD, et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol. 2005;98:421–424
  9. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912–917
  10. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the cardiovascular health study. Thromb Haemost. 1998;79:912–915
  11. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3–10
  12. The Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107:1117–1122
  13. Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost. 1998;80:878–880
  14. Longstreth WT, Rosendaal RF, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577–580
  15. Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A, Mendel T, et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost. 2001;7:346–350
  16. Austin H, Chimowitz MI, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, et al. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke. 2002;33:2762–2769
  17. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002;33:51–56
  18. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948–957
  19. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185–1190
  20. Lindhoff-Last E, Humpich M, Schmitt J, Rödiger S, Seifried E, Bauersachs R. MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost. 2002;8:163–167
  21. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306
  22. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I-9–I-16
  23. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155
  24. Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sorensen H, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006;4:1891–1896
  25. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am Heart J. 2000;139:371–377
  26. Muntner P, Garrett E, Klag MJ, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke. 2002;33:1209–1213
  27. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999–1004
  28. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease. Thromb Haemost. 2002;87:614–621
  29. French JK, Van de Water NS, Sutton TM, Lund M, Gao W, McDowell J, et al. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J. 2003;145:118–124
  30. Mansourati J, Da Costa A, Munier S, Mercier B, Tary B, Ferec C, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost. 2000;83:822–825
  31. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102–1108
  32. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. Von Willebrand factor and factor VIII:C in acute cerebrovascular disease: relationship to stroke subtype and mortality. Thromb Haemost. 1997;77:1104–1108
  33. Rice GI, Grant PJ. FVIII coagulant activity and antigen in subjects with ischaemic heart disease. Thromb Haemost. 1998;80:757–762
  34. Tracy RP, Arnold AM, Ettinger W, Fried L, Leilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:1776–1783
  35. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79–84
  36. Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001;21:731–738
  37. Levine SR. Hypercoagulable states and stroke: a selective review. CNS Spectr. 2005;10:567–578
  38. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–763
  39. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114:593–595
  40. The APASS Writing Committee . Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischaemic stroke. JAMA. 2004;291:576–584
  41. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis. 2005;20:105–112

PII: S0049-3848(07)00313-1

doi: 10.1016/j.thromres.2007.07.014

Thrombosis Research
Volume 121, Issue 6 , Pages 743-750 , 2008

Article Tools